{"id":"W2892903770","doi":"10.1080/14737140.2018.1528146","title":"Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review","year":2018,"lang":"en","type":"review","venue":"Expert Review of Anticancer Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Nivolumab; Atezolizumab; Cancer; Lung cancer; Internal medicine; Quality of life (healthcare); Oncology; Clinical trial; Systematic review; Melanoma; Ipilimumab; Head and neck cancer; MEDLINE; Intensive care medicine; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.002342162,0.0008844681,0.01465028,0.000280912,0.00004188637,0.000007770416,0.0004276224,0.000273633,0.000561486],"category_scores_gemma":[0.0002944944,0.000500865,0.001474114,0.001952457,0.0003779521,0.00008919017,0.00003522442,0.0003756532,0.00000923957],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006494203,"about_ca_system_score_gemma":0.002133473,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003401143,"about_ca_topic_score_gemma":0.00008840575,"domain_scores_codex":[0.9897084,0.001570308,0.006503514,0.000738574,0.0009947589,0.0004843949],"domain_scores_gemma":[0.9920083,0.0002454335,0.00564476,0.001288753,0.0006034585,0.0002093187],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0004333342,0.0005715766,0.0002078242,0.8711582,0.001559608,0.000001948346,0.0001183608,1.849908e-9,0.000001425193,0.000002254543,0.003722284,0.1222231],"study_design_scores_gemma":[0.002166916,0.001109357,0.00009251603,0.8330213,0.00072781,0.000008820586,0.00000720592,1.083488e-7,0.000006905077,3.838823e-7,0.1624692,0.0003895177],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00009969612,0.9859717,7.950599e-7,0.0007050683,0.000211055,0.01279191,0.0001060192,0.00003503137,0.00007865665],"genre_scores_gemma":[0.00002979937,0.992686,0.00005104844,0.005082332,0.0001143927,0.001645533,0.0001916459,0.0001215227,0.00007773585],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.1587469,"threshold_uncertainty_score":0.9999782,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06345455502091561,"score_gpt":0.4126376919410446,"score_spread":0.349183136920129,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}